Wenbin Wu

Wenbin Wu

Auto-generated profile, based on publicly available information

Wenbin Wu

Department of Cardiothoracic Surgery, Xuzhou Central Hospital , Xuzhou, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2020 in Postgraduate Medicine
Verified
Journal Article
Closed access
LLLei Liu
Lei Liu
LGLongbo Gong
Longbo Gong
MZMiao Zhang
Miao Zhang
WWWenbin Wu
Wenbin Wu
The role of thoracic duct ligation (TDL) during esophagectomy remains controversial. This review aimed to elucidate the effect of TDL on chylothorax and survival of the patients after esophagectomy...

28 February 2020 in Postgraduate Medicine
Verified
Journal Article
Closed access
CZChu Zhang
Chu Zhang
MZMiao Zhang
Miao Zhang
LGLongbo Gong
Longbo Gong
WWWenbin Wu
Wenbin Wu
Early oral feeding (EOF) is an important component of enhanced recovery after surgery (ERAS), but raises the concern of increased risk of anastomotic leakage (AL) in patients receiving esophagectomy. We searched PubMed, Web of Science, Scopus, Cochrane Library and Google Scholar from their inception to February 2020 for published articles that compared AL after EOF (oral feeding initiated within 3 postoperative day [POD] 3) vs. conventional feeding regimen (nil-by-mouth with enteral tube nutrition support, until oral feeding initiated since POD 4 and beyond) following esophagectomy. A total of 11 full articles were included in this review, including 5 registered randomized controlled trials (RCTs) and 6 observational studies that compared EOF with conventional care after esophagectomy. Meta-analysis was not possible due to significant heterogeneity, bias, and small sample sizes. Among the 11 included studies, 9 (including the 5 RCTs) showed that EOF did not increase AL rate, whereas the other 2 retrospective studies indicated that delayed oral feeding resulted in fewer AL. Based on the current evidence, EOF after esophagectomy probably does not increase the incidence of postoperative AL, and it is a promising strategy in line with the essence of fast-track surgery. More and better evidence from high-quality RCTs are still needed.

23 October 2020 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
LLLei Liu
Lei Liu
YLYuanyuan Liu
Yuanyuan Liu
LGLongbo Gong
Longbo Gong
MZMiao Zhang
Miao Zhang
WWWenbin Wu
Wenbin Wu
The current evidence regarding immunotherapy plus targeted therapy in esophageal neuroendocrine carcinoma (NEC) is lacking. Camrelizumab is a programmed cell death protein 1 inhibitor. Apatinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. A 50-year-old female was initially diagnosed as primary esophageal NEC. Neoadjuvant chemotherapy and Ivor Lewis esophagectomy were performed (ypT3N0M0, stage Ⅱ). Twenty months after the surgery, an isolated mediastinal lymph node recurrence of NEC was recorded. The specimen revealed a positive expression of vascular endothelial growth factor and programmed cell death ligand 1. The diseased lymph node was slightly enlarged after two cycles of first-line paclitaxel liposome and S-1. Second-line apatinib and S-1 for 2 months also resulted in progressive disease. Subsequently, third-line camrelizumab plus apatinib was continued for 5 months. The patient demonstrated a progression-free status for more than 10 months following the combination therapy. Meanwhile, relevant studies of camrelizumab in gastric or esophageal cancer were briefly reviewed. Based on the current evidence, camrelizumab is a promising agent for esophageal cancer. More prospective trials are warranted before a definite recommendation could be drawn.

5 June 2020 in Medicine
Verified
Journal Article
Open access
FKFeng-Wei Kong
Feng-Wei Kong
WWWei-Min Wang
Wei-Min Wang
LLLei Liu
Lei Liu
WWWen-Bin Wu
Wen-Bin Wu
XWXiang Wang
Xiang Wang
MZMiao Zhang
Miao Zhang
Rationale: Pulmonary sarcomatoid carcinoma (PSC) is an uncommon type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to the conventional chemoradiotherapy. To date, the optimal treatment for PSC has not been elucidated. Patient concerns: Three male patients including a 69-year-old smoker (Case 1), a 45-year-old non-smoker (Case 2), and a 69-year-old smoker (Case 3) were admitted because of cough, back pain, and loss of body weight respectively. Diagnoses: Radiographical examinations in these patients showed bulky intrathoracic lesions, which were pathologically diagnosed as PSC staging III–IV by computed tomography–guided percutaneous biopsy and endoscopy. Interventions: Immunotherapy was not covered by their health insurance and they refused immune checkpoint inhibitors for financial reasons. In addition, a radical resection was not appropriate due to the advanced staging of these lesions. Therefore, first-line albumin-bound paclitaxel (nab-paclitaxel, 260 mg/m2 of the body surface area) and carboplatin (area under curve 5) combined with oral apatinib (425 mg, daily) were administered empirically. Outcomes: Two patients achieved a partial response and the other case showed stable disease lasting for more than 6 months. However, 1 of them indicated progression on the 7-month follow up. Lessons: Nab-paclitaxel/carboplatin plus apatinib showed limited short-term efficacy in advanced, unresectable PSC. The rapid resistance of PSC to the current therapeutic regimen necessitates further researches, as more effective agents are urgently needed.

30 August 2022 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
WZWenlong Zheng
Wenlong Zheng
MZMiao Zhang
Miao Zhang
WWWenbin Wu
Wenbin Wu
HZHui Zhang
Hui Zhang
XZXinhui Zhang
Xinhui Zhang
Background: Pulmonary sequestration (PS) is a rare lesion with independent blood supply from an anomalous systemic artery. A timely resection is considered as the best treatment for PS. Three-dimensional computed tomography angiography (3D-CTA) has been widely utilized for precise thoracic surgery. This study aimed to investigate the role of preoperative 3D-CTA and resection simulation in uniportal video-assisted thoracoscopic surgery (VATS) anatomical lung surgery for PS.Methods: The data of 20 consecutive PS patents undergoing anatomic lung resection between April 2011 and May 2021 in a single centre were retrospectively reviewed. These patients were divided into the 3D-CTA group (10 patients) and the control group (10 patients) according to the initial surgical planning with or without 3D-CTA. The perioperative parameters regarding safety and fluency such as the incidence of conversion to open thoracotomy, operation time, blood loss, complications and chest tube duration were analyzed.Results: This cohort included 12 female and 8 male patients, with a mean age of 45 years old (range 24–60 years). Nine cases demonstrated recurrent febrile, cough, or hemoptysis; whereas the other 11 patients were asymptomatic on admission. Eighteen (90.0%) intralobar and 2 extralobar PS were confirmed, whereas 18 (90.0%) lesions were located in the left thorax. The feeding vessels originated from the thoracic aorta in 16 patients (80.0%), the abdominal aorta in 3 (15.0%), and the inferior phrenic artery in 1 patient (5.0%). There was no major bleeding or 30 days mortality. The initial surgical planning included 9 uniportal and 1 two-port VATS in the 3D-CTA group, as compared with 10 two-port VATS in the control group. Thirteen lobectomies, 5 segmentectomies and 2 mass excisions were performed. However, no conversion was needed in the 3D-CTA group; whereas 6 (60.0%) conversions (4 to multiple-port and 2 to thoracotomy) occurred in the control group, indicating a significant difference (P = 0.003). In addition, the operation time in the 3D-CTA group was significantly shorter than those in the control group [(108.5 ± 24.9) min vs. (154.5 ± 39.4) min,P = 0.006]. The other surgery-related outcomes were similar between the two groups.Conclusion: Preoperative 3D-CTA facilitates the safe and fluent performance of uniportal VATS anatomical lung resection for PS with shortened operation time and lessened surgical conversions.

5 February 2020 in IEEE/ACM Transactions on Networking
Verified
Journal Article
Closed access
Wei DongWei Dong
Wei Dong
Yi GaoYi Gao
Yi Gao
CCChenhong Cao
Chenhong Cao
XZXiaoyu Zhang
Xiaoyu Zhang
WWWenbin Wu
Wenbin Wu
Most sensor networks employ dynamic routing protocols so that the routing topology can be dynamically optimized with environmental changes. The routing behaviors can be quite complex with increasing network scale and environmental dynamics. Knowledge on the routing path of each packet is certainly a great help in understanding the complex routing behaviors, allowing effective performance diagnosis and efficient network management. We propose PAT, a universal sensornet path tracing approach. PAT includes an intelligent path encoding scheme that allows efficient decoding at the PC side. To make PAT more scalable, we propose techniques to accurately estimate the degree information by exploiting timing information, allowing more compact path encoding. Moreover, we employ subpath concatenation to infer excessively long paths with a high recovery probability. We propose an analytical model to quantify the benefits of PAT with varying network scale, network density, routing dynamics and packet delivery performance. We evaluate PAT's performance using testbed experiments, trace-driven study, and extensive simulations. Results show that PAT significantly outperforms existing approaches.